Turkish Journal of Medical Sciences最新文献

{"title":"Do the amplitude ratios of sensory nerve action potentials in the lower extremities have any diagnostic utility in distal diabetic polyneuropathy?","authors":"Işıl Yazici Gençdal, Nermin Görkem Şirin, İrem Ilgezdi, Ümmü Mutlu, Elif Kocasoy-Orhan, Mehmet Barış Baslo, Nevin Dinççağ, Ali Emre Öge","doi":"10.55730/1300-0144.6014","DOIUrl":"10.55730/1300-0144.6014","url":null,"abstract":"<p><strong>Background/aim: </strong>To investigate the diagnostic sensitivity of sural sensory nerve action potential (SNAP) to medial femoral cutaneous nerve and dorsal sural to sural SNAP amplitude ratios in patients with diabetic polyneuropathy.</p><p><strong>Materials and methods: </strong>Sural/radial (SRAR), sural/medial femoral cutaneous (SMFAR), and dorsal sural/sural (DSSAR) SNAP amplitude ratios were calculated in 22 controls and 46 patients with type 2 diabetes mellitus. Combined sensory scores (superficial peroneal, sural, dorsal sural, and medial plantar SNAPs), and amplitude ratio scores (SRAR, DSSAR, and SMFAR) were assessed. The parameters were compared statistically between the patient and control groups.</p><p><strong>Results: </strong>All SNAP amplitudes were significantly lower in patients as compared with those of the controls. Reduced medial plantar SNAP amplitude was the most frequent abnormality in the patient group. DSSAR and SMFAR, but not SRAR were found to have significant value in differentiating patients from controls with low sensitivity and moderate specificity. The combined sensory score improved the diagnostic accuracy for diabetic polyneuropathy, while the other combined scores add no additional value in this respect.</p><p><strong>Conclusion: </strong>Distal nerve conduction studies (NCSs) are most useful in diagnosing mild diabetic polyneuropathy. Although DSSAR and SMFAR can be moderately sensitive alternatives, particularly when used in combined scores, these ratios do not add any diagnostic value in patients with axonal polyneuropathies of similar severity.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"666-675"},"PeriodicalIF":1.2,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270288/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of the relationship between the triglyceride-glucose index and metabolic and hematological parameters in obese individuals.","authors":"Özge Baş Aksu, Feride Özkara, Rıfat Emral, Volkan Genç, Demet Çorapçioğlu, Mustafa Şahin","doi":"10.55730/1300-0144.6019","DOIUrl":"10.55730/1300-0144.6019","url":null,"abstract":"<p><strong>Background/aim: </strong>This research examined the association between the triglyceride-glucose (TyG) index and metabolic, hepatic, and hematologic variables in a population of severely obese subjects, with a focus on the assessment of glycemic control.</p><p><strong>Materials and methods: </strong>This retrospective study included 315 adult patients with a body mass index (BMI) ≥ 35 kg/m² who were evaluated for bariatric surgery. Participants were grouped according to HbA1c levels: those with HbA1c ≥ 6.5% and those with HbA1c < 6.5%. TyG, atherogenic index of plasma (AIP), fibrosis-4 (FIB-4), aspartate aminotransferase-to-platelet ratio index (APRI), and hematological inflammation markers were assessed and compared between groups. To investigate associations, correlation and regression analyses were conducted.</p><p><strong>Results: </strong>Individuals with HbA1c ≥ 6.5% had significantly higher TyG, AIP, APRI, and FIB-4 values than those with lower HbA1c. The TyG index showed a strong correlation with both HbA1c (r = 0.403, p < 0.001) and AIP (r = 0.866, p < 0.001), and was identified as an independent predictor of HbA1c, explaining 20.5% of its variance. Moderate correlations were also found between liver fibrosis scores and systemic inflammatory indices. No significant differences were observed in hematologic markers across HbA1c groups, suggesting a closer link between inflammation and obesity rather than glycemic status.</p><p><strong>Conclusion: </strong>The TyG index may serve as a practical and accessible marker for metabolic risk and glycemic control in obese individuals. Its integration with other noninvasive indices like AIP, APRI, and FIB-4 may support a more comprehensive evaluation of cardiometabolic and hepatic risk profiles in clinical settings.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"710-718"},"PeriodicalIF":1.2,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270320/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiometabolic risk factors and their association with carotid intima media thickness among patients with type 2 diabetes mellitus.","authors":"Christian Saleh","doi":"10.55730/1300-0144.6030","DOIUrl":"10.55730/1300-0144.6030","url":null,"abstract":"<p><p>Comment to Weerarathna TP, Lekamwasam S, Kodikara I, Wasana KGP, Fonseka L. Control of cardiometabolic risk factors and their association with carotid intima media thickness among patients with type 2 diabetes mellitus-single center experience in a developing country. (Turk J Med Sci. 2024 Jan 11; 54 (3): 545-554).</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"810-811"},"PeriodicalIF":1.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-year clinical follow-up of granulomatous lymphadenitis diagnosed via EBUS-TBNA in a tuberculosis-endemic region.","authors":"Hasret Gizem Kurt, Ayperi Öztürk, Melahat Uzel Şener, Figen Öztürk Ergür, Zeynep Tilbe Saymaz Guvanjov, Aydın Yilmaz","doi":"10.55730/1300-0144.6006","DOIUrl":"10.55730/1300-0144.6006","url":null,"abstract":"<p><strong>Background/aim: </strong>Granulomatous lymphadenitis is not a specific clinical diagnosis. In regions where tuberculosis (TB) is endemic, differentiating between various diseases presenting with granulomatous lymphadenitis poses a significant clinical challenge. This study aims to evaluate the etiological distribution of underlying conditions and to assess diagnosis changes observed during at least one year of follow-up in patients diagnosed with granulomatous lymphadenitis through endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).</p><p><strong>Materials and methods: </strong>A total of 4711 patients were included in the study, and 9353 lymph node samples were collected. Granulomatous lymphadenitis was identified in 791 patients, from whom 1505 lymph node samples were obtained. A cohort of 453 patients was monitored for at least 1 year, during which 873 lymph node samples were collected. The medical records of these patients were retrospectively reviewed in detail, and the final clinical diagnosis for each patient was established at the conclusion of the 1-year follow-up period.</p><p><strong>Results: </strong>Sarcoidosis was the most common final diagnosis, accounting for 52.3% of cases, while tuberculosis lymphadenitis was diagnosed in 42.6% of patients. Diagnostic procedures, including acid-fast bacteria (AFB) staining, culture, and TB-PCR, were performed in 94.3% of the cohort. Nonnecrotizing granulomatous lymphadenitis was identified in 8 patients with a history of extrathoracic malignancy; 5 were diagnosed with sarcoid-like reactions and 3 with TB lymphadenitis. Additionally, during the 1-year clinical follow-up period, the initial diagnosis was revised in 14 patients.</p><p><strong>Conclusion: </strong>Long-term follow-up of clinical progression and treatment response is crucial for precise diagnosis and management. The study findings suggest that routine TB-PCR and AFB testing on EBUS-TBNA-derived lymph node samples could enhance diagnostic precision.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"595-601"},"PeriodicalIF":1.2,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of adipose tissue-derived mesenchymal stem cells and bone marrow-derived mesenchymal stem cells in anosmic mice.","authors":"Burak Hazir, Alper Ceylan, Emin Ümit Bağriaçik, Duygu Dayanir, Betül Öğüt, Nihan Örüklü, Mücahit Yalçin, Berkay Şimşek, Muammer Melih Şahin","doi":"10.55730/1300-0144.6028","DOIUrl":"10.55730/1300-0144.6028","url":null,"abstract":"<p><strong>Background/aim: </strong>Anosmia, a serious condition that affects the sense of smell, has no universally agreed-upon treatment. Adult stem cells are considered a potential option for treating anosmia. This study aims to evaluate the efficacy of mesenchymal stem cells derived from different tissues in an anosmic mouse model induced by 3-methylindole (3-MI).</p><p><strong>Materials and methods: </strong>In our study, 36 mice with 3-MI-induced anosmia were divided into subgroups. Anosmia was confirmed by performing a food-finding test (FFT) in each group. Intranasal phosphate-buffered saline was administered to the first group, adipose tissue-derived mesenchymal stem cells (ADSCs) to the second group, and bone marrow-derived mesenchymal stem cells (BMSCs) to the third group. Stem cells were obtained from green fluorescent protein (GFP)-transgenic mice. Olfactory function was evaluated weekly using the FFTs. Mice were sacrificed at the second and fourth weeks following 3-MI injection and examined histopathologically.</p><p><strong>Results: </strong>Compared to the control group, stem cell-transplanted groups demonstrated significantly improved food-finding times measured at week 2 and week 4 FFTs following the 3-MI injection (respectively; p = 0.001, p = 0.008). Additionally, increased olfactory marker protein expression and olfactory epithelial thickness, along with reduced epithelial damage, were observed in the stem cell-transplanted groups compared to the control group (p < 0.05). Histologically, BMSCs showed greater efficacy than ADSCs in promoting olfactory regeneration. Furthermore, GFP+ cells were detected in the olfactory epithelium and olfactory bulbs of the stem cell-transplanted groups.</p><p><strong>Conclusion: </strong>It was observed that intranasally transplanted stem cells could reach the damaged olfactory region and enhance olfactory regeneration and functional recovery. Both ADSCs and BMSCs were effective in treatment and appear to be promising therapeutic modalities.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"792-801"},"PeriodicalIF":1.2,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating leflunomide and methotrexate combination vs. monotherapy in rheumatoid and psoriatic arthritis.","authors":"Mete Kara, Gülay Alp, Mete Pekdiker, Sertaç Ketenci, Annamaria Porreca, Haluk Cinakli","doi":"10.55730/1300-0144.6010","DOIUrl":"10.55730/1300-0144.6010","url":null,"abstract":"<p><strong>Background/aim: </strong>Methotrexate (MTX) and leflunomide (LEF) are conventional synthetic disease-modifying antirheumatic drugs (DMARDs) commonly used for treating rheumatoid arthritis (RA) and psoriatic arthritis (PsA), either as monotherapies or in combination. This study aimed to compare the adverse effects (AEs) and efficacy of combined use of MTX plus LEF with monotherapy in RA and PsA patients.</p><p><strong>Materials and methods: </strong>This study included 528 patients (385 RA and 143 PsA) with at least 6 months of follow-up. Disease activity was assessed using DAS-28 CRP and DAPSA, and treatment-related AEs were classified based on specific MedDRA categories.</p><p><strong>Results: </strong>The cumulative incidence of AEs in patients with RA treated with MTX, LEF, and MTX plus LEF was 23.8%, 28.2%, and 19.2%, respectively; in PsA patients, 18.1%, 30%, and 23.3%, respectively. None of the groups were superior to each other in terms of general AEs between monotherapy and in combination. LEF monotherapy in RA was associated with more neurological AEs and hypertension. Compared to monotherapy, MTX plus LEF demonstrated greater reductions in disease activity, a more substantial decrease in glucocorticoid doses, and lower utilization of biological/targeted DMARDs (b/tsDMARDs) in both RA and PsA. In univariate analysis, MTX dosage, initial DAS28 CRP, and b/tsDMARD initiation were predictors of low disease activity (LDA) in RA. In multivariate analysis, MTX dosage (95% CI 1.02-1.59, OR = 1.27, p = 0.031) and initial DAS28-CRP (95% CI 2.14-10.90, OR = 4.38, p < 0.001) were found to be independently associated with LDA in RA. In PsA, the factors associated with LDA were initial DAPSA and disease duration in univariate analysis. Only disease duration was found to be an independent predictor in multivariate analysis (95% CI, 1.02-1.38, OR = 1.17 p = 0.039).</p><p><strong>Conclusion: </strong>Adding LEF to MTX or vice versa may serve as a valuable, safe, and effective alternative in situations where b/tsDMARD therapy is challenging.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"632-643"},"PeriodicalIF":1.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does dexmedetomidine infusion reduce the postoperative analgesic need in lumbar disc surgery?","authors":"Sibel Çatalca, Özlem Özmete, Numan Berk, Soner Çivi, Emre Durdağ, Caner Incekaş, Nesrin Bozdoğan Özyilkan","doi":"10.55730/1300-0144.5991","DOIUrl":"https://doi.org/10.55730/1300-0144.5991","url":null,"abstract":"<p><strong>Background/aim: </strong>Patients experience moderate-to-severe pain, especially in the first days after lumbar disc surgery. Poorly controlled pain in the postoperative period negatively affects patient outcomes. Dexmedetomidine is a highly selective α2 adrenoceptor agonist with demonstrated analgesic efficacy. However, conflicting results have been reported in the current literature regarding the efficacy of dexmedetomidine in this surgery. In this study, we tested the hypothesis that dexmedetomidine safely improves pain scores and reduces opioid consumption in lumbar microdiscectomy.</p><p><strong>Materials and methods: </strong>Medical records of patients who underwent lumbar microdiscectomy with general anesthesia between January 2023 and October 2023 were retrospectively reviewed. Patients who met the inclusion criteria were divided into two groups as those who did not receive dexmedetomidine infusion (Group A) and those who received dexmedetomidine infusion (Group B). Patients in Group B received a loading dose of 1 μg/kg dexmedetomidine followed by a maintenance infusion of 0.5 μg/kg/h. The primary outcome of our study was postoperative fentanyl consumption at the 24^th h. Secondary outcomes of our study included need for fentanyl in the recovery unit, postoperative pain scores at the 2^nd, 6^th, 12^th, and 24^th h and fentanyl consumption at the 2^nd, 6^th, and 12^th h and perioperative complications.</p><p><strong>Results: </strong>A total of 68 patients were included in our study, 34 patients in each group. The number of patients requiring fentanyl in the recovery unit and the dose of fentanyl administered were similar in both groups (p = 0.223 and p = 0.373, respectively). There was no statistical difference in the pain scores, opioid consumption, and perioperative complications at the 2^nd, 6^th, 12^th, and 24^th h after surgery in patients receiving dexmedetomidine compared to the control group (p > 0.05).</p><p><strong>Conclusion: </strong>Intraoperative dexmedetomidine infusion did not reduce postoperative pain intensity and opioid consumption in patients undergoing lumbar microdiscectomy under general anesthesia.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 2","pages":"470-481"},"PeriodicalIF":1.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058006/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-40 levels in treatment-naive and methotrexate-treated rheumatoid arthritis patients.","authors":"Hamdi Oğuzman, Mete Pekdiker","doi":"10.55730/1300-0144.6013","DOIUrl":"10.55730/1300-0144.6013","url":null,"abstract":"<p><strong>Background/aim: </strong>Rheumatoid arthritis (RA) is an autoimmune disease that is characterized by persistent inflammation and progressive damage to the joints. In this study, it was aimed to explore the role of interleukin (IL)-40, a newly discovered cytokine, in the pathogenesis of RA. We also aimed to investigate the relationship between IL-40 and other cytokines such as IL-4, transforming growth factor (TGF)-β1 and tumor necrosis factor (TNF)-α.</p><p><strong>Materials and methods: </strong>This single-center, cross-sectional study included 87 participants divided into three groups: healthy controls (n = 29), newly diagnosed RA patients (n = 29), and RA patients with remission under methotrexate (MTX) monotherapy (n = 29). Serum samples were collected and analyzed for IL-40, IL-4, TGF-β1 and TNF-α levels using ELISA. Disease activity score, presence of autoantibodies and other relevant clinical data were obtained from hospital electronic records.</p><p><strong>Results: </strong>Elevated IL-40 levels were found in the newly diagnosed RA patients and in those treated with MTX compared to the control group (p < 0.001). Logistic regression analysis confirmed IL-40 as an independent predictor in the newly diagnosed (OR = 1.023, 95% CI: 1.010-1.035, p = 0.002) and RA MTX-treated patients (OR = 1.023, 95% CI: 1.011-1.036, p < 0.001). IL-40 levels remained unchanged in the newly diagnosed RA group compared to RA patients in the MTX-treated group. In the dual-seropositive patients, TGF-β1 was lower in the MTX-treated RA patients compared to the naive patients (p = 0.013) and in the dual-seronegative patients, TNF-α was decreased in the MTX-treated RA patients in comparison to naive patients (p = 0.043).</p><p><strong>Conclusion: </strong>This study demonstrates that IL-40 levels are elevated in RA patients and highlights its potential role in RA. The fact that IL-40 levels did not change despite the antiinflammatory effects of MTX suggests that IL-40 is involved in immunological pathways that are less responsive to treatment.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 3","pages":"658-665"},"PeriodicalIF":1.2,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270298/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.","authors":"Melikenur Türkol, Türker Bilgen","doi":"10.55730/1300-0144.5997","DOIUrl":"https://doi.org/10.55730/1300-0144.5997","url":null,"abstract":"<p><strong>Background/aim: </strong>Liraglutide as a long-acting glucagon-like peptide drug has anti-hyperglycemic and antiobesity effects. G protein-coupled receptors (GPCRs) are well-known drug target molecules that conduct critical signaling pathways related with diseases. Research has confirmed the role of many GPCRs genes in the regulation of pancreatic beta cell functions and insulin secretion. Liraglutide dependent expressional changes in GPCR genes may let us determine new drug targets.</p><p><strong>Materials and methods: </strong>Therefore, we investigated the changes in expression of GPR75, GPR56, GLP1R, M3R, and CB1R genes, which are the GPCR family members, in response to liraglutide treatment in the NIT-1 mouse pancreatic beta cells in this study. Changes at the mRNA levels of these GPCR genes were determined by a qPCR and the ddCT method, and using a control gene and untreated control groups.</p><p><strong>Results: </strong>We found statistically significant increases at the mRNA levels of GPR75, GPR56, M3R, and CB1R genes with 10nM of liraglutide at min 60, while there was no time and dose-dependent change in all of the genes investigated. We detected that the GLP1R gene expressions were stable amongst different time points and doses of liraglutide, except for a statistically significant decrease in the GLP1R gene expression in response to 1000nM of liraglutide treatment compared to 10nM and 100nM concentrations.</p><p><strong>Conclusion: </strong>Our results indicate that in vitro liraglutide administration in pancreatic beta cells appears to increase the expressions of GPR75, GPR56, M3R and CB1R genes which have already been related to insulin secretion and beta cell survive. Liraglutide may exert this effect through the GLP1R or other cellular pathways undescribed yet. Combined usage of liraglutide and the specific ligands of GPR75, GPR56, M3R, and CB1R may provide a better response in terms of insulin secretion and beta cell survival, making them good targets for antidiabetic and antiobesity therapy.</p>","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 2","pages":"525-530"},"PeriodicalIF":1.2,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058015/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144048291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epstein Barr virus associated venous thromboembolism.","authors":"Yeliz Çiçek, Ali Mert","doi":"10.55730/1300-0144.5998","DOIUrl":"https://doi.org/10.55730/1300-0144.5998","url":null,"abstract":"","PeriodicalId":23361,"journal":{"name":"Turkish Journal of Medical Sciences","volume":"55 2","pages":"531-532"},"PeriodicalIF":1.2,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12058028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144034666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}